Clinical Trials
10 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT03114254 2022-11-18
JAVA-P
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03295565 2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3 Completed
NCT02166658 2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01594918 2017-07-21
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT02035124 2016-02-11
Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel
SCRI Development Innovations, LLC
Phase 2 Withdrawn
NCT01541007 2015-11-02
ConCab
Karolinska University Hospital
Phase 2 Completed
NCT01830231 2014-01-28
Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Associació per a la Recerca Oncologica, Spain
Phase 2/3 Unknown